The Ledger ResearchPrivate

The Front Office

Scouting report · TNDM

Leigh A. Vosseller

  • EVP, Chief Financial Officer & Treasurer, TNDM since 2018-01src

Tandem's CFO since January 2018; joined as VP Finance in 2013

—thin record

Not ranked yet

Scouting sheet

as of 24 Sep 2026
Delivers guidance—no promises on the record yet
Answers the question—no call reviewed yet
Capital allocation—company not reviewed yet
Pay design67revenue, strategic, ebitda, relative tsr, time only · 97.3% for · company lost money
Skin in the game—no holding or price on file
Age
53src
In the role
9 yr
Promises scored
0
Hit rate
—
Dodges / 100 answers
—
Airtime on calls
—
Every promise, oldest firstno scored promises yet

What to weigh

Red flag 1

  • The CFO reports to her domestic partner, the CEO. It is disclosed and controlled (compensation committee sets both packages, audit committee added controls), but the two financial-reporting certifiers share a householdsrc

Watch 2

  • The 2025 bonus paid 87% of target although worldwide revenue ($1.015bn) missed the $1.054bn target and the revenue component earned 81%src
  • The May 2026 equity grant reported on Form 4 was 62,657 time-vesting RSUs, with no PSU reportedsrc

In their favour 1

  • Stock ownership guideline is 1x salary; the proxy says all executives complied or were within the phase-in, and she bought shares in the open market in 2025src

Career

  1. 2018 – now
    Tandem Diabetes Caresrc
    EVP, Chief Financial Officer & Treasurer (EVP since June 2018)
    Also responsible for information technology. Salary raised from $345,000 to $386,250 effective 2018-06-18 (8K-2018-06-15)
  2. 2018 – 2018
    Tandem Diabetes Caresrc
    SVP, Chief Financial Officer & Treasurer (from 2018-01-01)
  3. 2017 – 2017
    Tandem Diabetes Caresrc
    SVP, Finance (from August 2017)
  4. 2013 – 2017
    Tandem Diabetes Caresrc
    VP, Finance
  5. 2011 – 2013
    Genoptixsrc
    VP & Chief Financial Officer
    The 2018 proxy calls it 'Genoptix, fka Novartis company'
  6. 2008 – 2011
    Genoptix, Inc.src
    Finance roles before becoming CFO (titles not stated)
    Before Genoptix she held a senior finance position at Biosite Incorporated, helping build its infrastructure for international expansion; years not stated

Not located: Months of the 2013 move from Genoptix to Tandem not stated; the Biosite years and anything earlier not located in any source searched

Achievements

  • Has been Tandem's CFO for more than eight years, promoted from inside after joining as VP Finance in 2013src
  • Was VP & CFO of Genoptix from 2011, having joined it in 2008, before moving to Tandemsrc
  • Tandem passed $1bn of annual sales in 2025 and reported positive free cash flow in Q3 and Q4 2025src
  • Bought 13,720 shares in the open market at about $10.89 on 2025-08-08, the day after the stock fell on the t:slim X2 speaker correctionsrc

Education

  • Missouri State University, BS Accountingsrc

Background

  • Family She and the CEO, John Sheridan, are in a personal relationship and share a primary residence; disclosed since the 2019 CEO succession. She reports to him, neither sets the other's pay, and the audit committee added internal controlssrc
  • Giving Director and treasurer of Girls Inc. of San Diego, a non-profit running STEM programmes for underserved girls, since January 2021src
  • Legal Named defendant with the CEO in Lowe v. Tandem Diabetes Care (S.D. Cal., filed 2023-09-08) over 2022 sales trends and forecasts; dismissed with prejudice on 2024-06-04 after the plaintiffs did not amendsrc
  • Other The proxy reports no Item 401(f) legal proceedings for any director or executive officersrc

The promise ledger

No promise on the record yet: the research routine has not scored this company's guidance.

Sources

11
  1. Filing Tandem Diabetes Care DEF 14A (accession 0001438133-26-000034) · 2026-04-07
  2. Filing Tandem Diabetes Care DEF 14A (accession 0001564590-18-009319) · 2018-04-26
  3. Filing Tandem Diabetes Care 8-K Items 5.02/5.07, CFO salary increase (0001564590-18-015708) · 2018-06-15
  4. Filing Tandem Diabetes Care 8-K Items 2.02/5.02, CEO succession plan and family-relationship disclosure (0001564590-19-004461) · 2019-02-26
  5. Filing Tandem Diabetes Care 8-K Items 3.03/5.02/5.07, 2026 annual meeting results (0001438133-26-000070) · 2026-05-21
  6. Filing Tandem Diabetes Care 10-Q for Q3 2024, Note on legal matters (0001438133-24-000201) · 2024-11-06
  7. Filing SEC XBRL companyconcept us-gaap/NetIncomeLoss, CIK 1438133 (FY2025 10-K, 0001438133-26-000010) · 2026-02-19
  8. Filing Form 4, Leigh A. Vosseller (reporting CIK 1726322), open-market purchase of 2025-08-08 (0001438133-25-000163) · 2025-08-11
  9. Filing Form 4, Leigh A. Vosseller, RSU grant of 2026-05-29 (0001438133-26-000111) · 2026-06-02
  10. Filing Form 4, Leigh A. Vosseller, RSU vesting and tax withholding of 2026-08-15 (0001438133-26-000132) · 2026-08-18
  11. Call transcript TNDM Q2 2026 earnings call (2026-08-06), ROIC.ai